Samsara Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Samsara Inc trades at $41.5 (market cap $23.72B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: Samsara Inc is far larger — about 10.4× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Samsara Inc is trading nearer its 52-week high, SELLAS Life Sciences Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| IOT | SLS | |
|---|---|---|
Market Cap | $23.72B | $2.28B |
Volume | 4,096,683 | 3,128,960 |
Sector | Technology | Health |
52-Week High | $45.22 | $15.46 |
52-Week Low | $24.25 | $1.39 |
Typical Hold Time | 19 Days | — |
Enterprise Value | $22.96B | $2.15B |
Signals from Pluang's Aura AI — not financial advice
Samsara Inc. (IOT) trades at $40.51, down 2.95% on the day, but maintains a bullish technical outlook with strong analyst support. The company reported robust Q2 2027 results, beating earnings estimates with $0.20 EPS versus $0.16 expected, and achieved 30% year-over-year revenue growth. Recent partnerships and product launches, like the Laval Rocket sponsorship and Samsara MCP, highlight ongoing business expansion.
The stock offers upside to the $51.15 consensus price target, driven by solid fundamentals and institutional accumulation. However, elevated valuation multiples (P/E 270.07, P/S 12.79) and negative net income in 2025 pose risks if growth moderates. Positive cash flow trends and a 75% buy rating from analysts support a constructive outlook, though investors should monitor competitive pressures and execution on profitability goals.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →